Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637825 | 1.00 | PIK3CA (0.53) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL1637347 | 0.88 | PIK3CA (0.53) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL1637354 | 0.88 | PIK3CA (0.53) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL24714518 | 0.87 | PIK3CB (0.41) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL29160434 | 0.85 | PIK3CA (0.50) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL1637724 | 0.85 | PIK3CB (0.59) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL24713841 | 0.85 | PIK3CA (0.50) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL29826321 | 0.85 | PIK3CA (0.50) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL1637720 | 0.85 | PIK3CB (0.59) | PIK3CAMTORPRKDCPIK3CBPIK3CD | |
| SCHEMBL1638322 | 0.85 | PRKDC (0.55) | PIK3CAPRKDCPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| EP-2697220-B1 | CHROMENONE COMPOUNDS AS PI 3-KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| US-9029374-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2493870-B1 | CHROMENONE DERIVATIVES WITH ANTI -TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2014-12-17 | — | — | EP | disclosed |
| US-20140194419-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2014-07-10 | — | — | US | disclosed |
| EP-2697220-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2014-02-19 | — | — | EP | disclosed |
| US-20140038937-A1 | Chromenone Derivatives | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-8530470-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2013-09-10 | — | — | US | disclosed |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA INTELLECTUAL PROPERTY (GB) | 2013-06-20 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885MTOR 1120/4885PRKDC 2876/4885 |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885MTOR 1120/4885PRKDC 2876/4885 |
| US-20140038937-A1 | Chromenone Derivatives | RB1, CYP11B1, CCND1 | PIK3CA 1609/4885MTOR 703/4885PRKDC 2899/4885 |
| US-20140194419-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885MTOR 1120/4885PRKDC 2876/4885 |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND1 | PIK3CA 1609/4885MTOR 703/4885PRKDC 2899/4885 |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885MTOR 1120/4885PRKDC 2876/4885 |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CA 2099/4885MTOR 1120/4885PRKDC 2876/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | PIK3CA 1/4885MTOR 83/4885PRKDC 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.